| Short Description | CVX Code | Vaccine status | Vaccine Group Name | CVX for Vaccine Group |
|---|
| DTP | 01 | Inactive | DTAP | 107 |
| OPV, trivalent | 02 | Inactive | POLIO | 89 |
| MMR | 03 | Active | MMR | 03 |
| M/R | 04 | Inactive | MMR | 03 |
| measles | 05 | Inactive | MMR | 03 |
| rubella | 06 | Inactive | MMR | 03 |
| mumps | 07 | Inactive | MMR | 03 |
| Hep B, adolescent or pediatric | 08 | Active | HepB | 45 |
| Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | 09 | Active | Td | 139 |
| IPV | 10 | Active | POLIO | 89 |
| pneumococcal conjugate PCV 7 | 100 | Inactive | PneumoPCV | 152 |
| typhoid, ViCPs | 101 | Active | TYPHOID | 91 |
| DTP-Hib-Hep B | 102 | Non-US | HIB | 17 |
| DTP-Hib-Hep B | 102 | Non-US | DTAP | 107 |
| DTP-Hib-Hep B | 102 | Non-US | HepB | 45 |
| meningococcal C conjugate | 103 | Inactive | MENING | 108 |
| Hep A-Hep B | 104 | Active | HepA | 85 |
| Hep A-Hep B | 104 | Active | HepB | 45 |
| vaccinia (smallpox) diluted | 105 | Inactive | Orthopoxvirus | 325 |
| DTaP, 5 pertussis antigens | 106 | Active | DTAP | 107 |
| DTaP, unspecified formulation | 107 | Inactive | DTAP | 107 |
| meningococcal ACWY, unspecified formulation | 108 | Inactive | MENING | 108 |
| pneumococcal, unspecified formulation | 109 | Inactive | PneumoPCV | 152 |
| pneumococcal, unspecified formulation | 109 | Inactive | PneumoPPV | 33 |
| DTaP-Hep B-IPV | 110 | Active | DTAP | 107 |
| DTaP-Hep B-IPV | 110 | Active | HepB | 45 |
| DTaP-Hep B-IPV | 110 | Active | POLIO | 89 |
| Influenza, live, trivalent, intranasal, PF | 111 | Active | FLU | 88 |
| Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | 113 | Active | Td | 139 |
| meningococcal MCV4P | 114 | Active | MENING | 108 |
| Tdap | 115 | Active | TDAP | 115 |
| rotavirus, pentavalent | 116 | Active | ROTAVIRUS | 122 |
| HPV, bivalent | 118 | Inactive | HPV | 137 |
| rotavirus, monovalent | 119 | Active | ROTAVIRUS | 122 |
| DTaP-Hib-IPV | 120 | Active | DTAP | 107 |
| DTaP-Hib-IPV | 120 | Active | POLIO | 89 |
| DTaP-Hib-IPV | 120 | Active | HIB | 17 |
| zoster live | 121 | Inactive | ZOSTER | 188 |
| rotavirus, unspecified formulation | 122 | Inactive | ROTAVIRUS | 122 |
| influenza, H5N1-1203 | 123 | Inactive | H5N1 flu | 123 |
| Novel Influenza-H1N1-09, nasal | 125 | Inactive | H1N1 flu | 128 |
| Novel influenza-H1N1-09, preservative-free | 126 | Inactive | H1N1 flu | 128 |
| Novel influenza-H1N1-09 | 127 | Inactive | H1N1 flu | 128 |
| Novel Influenza-H1N1-09, all formulations | 128 | Inactive | H1N1 flu | 128 |
| Japanese Encephalitis, unspecified formulation | 129 | Inactive | Japanese encephalitis | 129 |
| DTaP-IPV | 130 | Active | POLIO | 89 |
| DTaP-IPV | 130 | Active | DTAP | 107 |
| DTaP-IPV-HIB-HEP B, historical | 132 | Inactive | DTAP | 107 |
| DTaP-IPV-HIB-HEP B, historical | 132 | Inactive | HIB | 17 |
| DTaP-IPV-HIB-HEP B, historical | 132 | Inactive | POLIO | 89 |
| DTaP-IPV-HIB-HEP B, historical | 132 | Inactive | HepB | 45 |
| Pneumococcal conjugate PCV 13 | 133 | Active | PneumoPCV | 152 |
| Japanese Encephalitis IM | 134 | Active | Japanese encephalitis | 129 |
| Influenza, high-dose, trivalent, PF | 135 | Active | FLU | 88 |
| Meningococcal MCV4O | 136 | Active | MENING | 108 |
| HPV, unspecified formulation | 137 | Inactive | HPV | 137 |
| Td (adult) | 138 | Inactive | Td | 139 |
| Td(adult) unspecified formulation | 139 | Inactive | Td | 139 |
| Influenza, split virus, trivalent, PF | 140 | Active | FLU | 88 |
| Influenza, split virus, trivalent, preservative | 141 | Active | FLU | 88 |
| Adenovirus types 4 and 7 | 143 | Active | ADENO | 82 |
| influenza, seasonal, intradermal, preservative free | 144 | Inactive | FLU | 88 |
| DTaP,IPV,Hib,HepB | 146 | Active | DTAP | 107 |
| DTaP,IPV,Hib,HepB | 146 | Active | HIB | 17 |
| DTaP,IPV,Hib,HepB | 146 | Active | HepB | 45 |
| DTaP,IPV,Hib,HepB | 146 | Active | POLIO | 89 |
| meningococcal MCV4, unspecified formulation | 147 | Inactive | MENING | 108 |
| Meningococcal C/Y-HIB PRP | 148 | Inactive | MENING | 108 |
| Meningococcal C/Y-HIB PRP | 148 | Inactive | HIB | 17 |
| Influenza, live, quadrivalent, intranasal | 149 | Active | FLU | 88 |
| influenza, split (incl. purified surface antigen) | 15 | Inactive | FLU | 88 |
| Influenza, split virus, quadrivalent, PF | 150 | Active | FLU | 88 |
| influenza nasal, unspecified formulation | 151 | Inactive | FLU | 88 |
| Pneumococcal Conjugate, unspecified formulation | 152 | Inactive | PneumoPCV | 152 |
| Influenza, MDCK, trivalent, PF | 153 | Active | FLU | 88 |
| Influenza, recombinant, trivalent, PF | 155 | Active | FLU | 88 |
| Influenza, split virus, quadrivalent, preservative | 158 | Active | FLU | 88 |
| influenza, whole | 16 | Inactive | FLU | 88 |
| Influenza A monovalent (H5N1), ADJUVANTED-2013 | 160 | Active | H5N1 flu | 123 |
| Influenza, injectable,quadrivalent, preservative free, pediatric | 161 | Active | FLU | 88 |
| meningococcal B, recombinant | 162 | Active | MeningB | 164 |
| meningococcal B, OMV | 163 | Active | MeningB | 164 |
| meningococcal B, unspecified | 164 | Inactive | MeningB | 164 |
| HPV9 | 165 | Active | HPV | 137 |
| influenza, intradermal, quadrivalent, preservative free | 166 | Inactive | FLU | 88 |
| Influenza, adjuvanted, trivalent, PF | 168 | Active | FLU | 88 |
| Hib, unspecified formulation | 17 | Inactive | HIB | 17 |
| DTAP/IPV/HIB - non-US | 170 | Non-US | POLIO | 89 |
| DTAP/IPV/HIB - non-US | 170 | Non-US | HIB | 17 |
| DTAP/IPV/HIB - non-US | 170 | Non-US | DTAP | 107 |
| Influenza, MDCK, quadrivalent, PF | 171 | Active | FLU | 88 |
| cholera, WC-rBS | 172 | Non-US | cholera | 26 |
| cholera, BivWC | 173 | Non-US | cholera | 26 |
| cholera, live attenuated | 174 | Active | cholera | 26 |
| Rabies - IM Diploid cell culture | 175 | Active | RABIES | 90 |
| Rabies - IM fibroblast culture | 176 | Active | RABIES | 90 |
| PCV10 | 177 | Non-US | PneumoPCV | 152 |
| rabies, intramuscular injection | 18 | Inactive | RABIES | 90 |
| Yellow fever vaccine live - alt | 183 | Active | YELLOWFEVER | 184 |
| Yellow fever, unspecified | 184 | Inactive | YELLOWFEVER | 184 |
| Influenza, recombinant, quadrivalent, PF | 185 | Active | FLU | 88 |
| Influenza, MDCK, quadrivalent, preservative | 186 | Active | FLU | 88 |
| zoster recombinant | 187 | Active | ZOSTER | 188 |
| zoster, unspecified formulation | 188 | Inactive | ZOSTER | 188 |
| HepB-CpG | 189 | Active | HepB | 45 |
| BCG | 19 | Active | BCG | 19 |
| Hep A-Hep B, pediatric/adolescent | 193 | Non-US | HepB | 45 |
| Hep A-Hep B, pediatric/adolescent | 193 | Non-US | HepA | 85 |
| Influenza, Southern Hemisphere | 194 | Inactive | FLU | 88 |
| DT, IPV adsorbed | 195 | Non-US | POLIO | 89 |
| DT, IPV adsorbed | 195 | Non-US | Td | 139 |
| Td, adsorbed, preservative free, adult use, Lf unspecified | 196 | Active | Td | 139 |
| Influenza, high-dose, quadrivalent, PF | 197 | Active | FLU | 88 |
| DTaP | 20 | Active | DTAP | 107 |
| influenza, Southern Hemisphere, pediatric, preservative free | 200 | Active | FLU | 88 |
| Influenza, Southern Hemisphere, quadrivalent, PF | 201 | Active | FLU | 88 |
| influenza, Southern Hemisphere, quadrivalent, with preservative | 202 | Active | FLU | 88 |
| meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | 203 | Active | MENING | 108 |
| Ebola Zaire vaccine, live, recombinant, 1mL dose | 204 | Active | Ebola | 214 |
| Influenza, adjuvanted, quadrivalent, PF | 205 | Active | FLU | 88 |
| Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection | 206 | Active | Orthopoxvirus | 325 |
| COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | 207 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | 208 | Inactive | COVID-19 | 213 |
| varicella | 21 | Active | VARICELLA | 21 |
| COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | 210 | Non-US | COVID-19 | 213 |
| COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | 211 | Inactive | COVID-19 | 213 |
| COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | 212 | Inactive | COVID-19 | 213 |
| SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 213 | Inactive | COVID-19 | 213 |
| Ebola, unspecified | 214 | Inactive | Ebola | 214 |
| Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | 215 | Active | PneumoPCV | 152 |
| Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | 216 | Active | PneumoPCV | 152 |
| COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | 217 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | 218 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | 219 | Inactive | COVID-19 | 213 |
| DTP-Hib | 22 | Inactive | DTAP | 107 |
| DTP-Hib | 22 | Inactive | HIB | 17 |
| HepB recombinant, 3-antigen, Al(OH)3 | 220 | Inactive | HepB | 45 |
| COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | 221 | Inactive | COVID-19 | 213 |
| Tick-borne encephalitis, unspecified | 222 | Inactive | Tick-borne encephalitis | 222 |
| Tick-borne encephalitis, inactivated, PF, 0.25mL | 223 | Active | Tick-borne encephalitis | 222 |
| Tick-borne encephalitis, inactivated, PF, 0.5mL | 224 | Active | Tick-borne encephalitis | 222 |
| COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | 225 | Never Active | COVID-19 | 213 |
| COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | 226 | Never Active | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | 227 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | 228 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | 229 | Inactive | COVID-19 | 213 |
| plague | 23 | Inactive | Plague | 23 |
| COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | 230 | Inactive | COVID-19 | 213 |
| influenza, Southern Hemisphere, high-dose, quadrivalent | 231 | Active | FLU | 88 |
| Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | 24 | Active | ANTHRAX | 319 |
| typhoid, oral | 25 | Active | TYPHOID | 91 |
| cholera, unspecified formulation | 26 | Inactive | cholera | 26 |
| DT (pediatric) | 28 | Inactive | DTAP | 107 |
| COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | 300 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | 301 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | 302 | Inactive | COVID-19 | 213 |
| RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | 303 | Active | RSV | 304 |
| Respiratory syncytial virus (RSV), unspecified | 304 | Inactive | RSV | 304 |
| RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | 305 | Active | RSV | 304 |
| RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | 306 | Active | RSV | 304 |
| RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | 307 | Active | RSV | 304 |
| COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | 308 | Inactive | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | 309 | Active | COVID-19 | 213 |
| Hep A, pediatric, unspecified formulation | 31 | Inactive | HepA | 85 |
| COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | 310 | Active | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | 311 | Active | COVID-19 | 213 |
| COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | 312 | Active | COVID-19 | 213 |
| COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | 313 | Active | COVID-19 | 213 |
| Respiratory syncytial virus (RSV) vaccine, unspecified | 314 | Inactive | RSV | 304 |
| Respiratory syncytial virus (RSV) MAB, unspecified | 315 | Inactive | RSV | 304 |
| Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | 316 | Active | MENING | 108 |
| Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | 316 | Active | MeningB | 164 |
| Chikungunya live attenuated vaccine, 0.5 mL, PF | 317 | Active | Chikungunya | 317 |
| Anthrax, post-exposure prophylaxis | 318 | Active | ANTHRAX | 319 |
| Anthrax vaccine, unspecified | 319 | Inactive | ANTHRAX | 319 |
| meningococcal MPSV4 | 32 | Inactive | MENING | 108 |
| Influenza, MDCK, trivalent, preservative | 320 | Active | FLU | 88 |
| Influenza-avian, H5N8, monovalent, PF | 321 | Active | FLU-Avian-H5 | 323 |
| Influenza-avian, H5N8, monovalent, preservative | 322 | Active | FLU-Avian-H5 | 323 |
| Influenza-avian, H5, unspecified formulation | 323 | Inactive | FLU-Avian-H5 | 323 |
| Poliovirus, inactivated, fractional-dose (fIPV) | 324 | Non-US | POLIO | 89 |
| Vaccinia (smallpox, monkeypox), unspecified | 325 | Inactive | Orthopoxvirus | 325 |
| RSV, mRNA, injectable, PF | 326 | Active | RSV | 304 |
| Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | 327 | Active | PneumoPCV | 152 |
| Meningococcal oligosaccharide (MenACWY), (MenB), PF | 328 | Active | MeningB | 164 |
| Meningococcal oligosaccharide (MenACWY), (MenB), PF | 328 | Active | MENING | 108 |
| Chikungunya, VLP, recombinant, 0.8 mL, PF | 329 | Active | Chikungunya | 317 |
| pneumococcal polysaccharide PPV23 | 33 | Active | PneumoPPV | 33 |
| Dengue fever, unspecified | 330 | Inactive | DENGUE | 330 |
| Influenza, Southern Hemisphere, trivalent, PF | 331 | Active | FLU | 88 |
| RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF | 332 | Active | RSV | 304 |
| Influenza, live, trivalent, intranasal, self/caregiver admin, PF | 333 | Active | FLU | 88 |
| COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL | 334 | Active | COVID-19 | 213 |
| Influenza, Southern Hemisphere, high-dose, trivalent, PF | 337 | Active | FLU | 88 |
| tetanus toxoid, adsorbed | 35 | Inactive | Td | 139 |
| yellow fever live | 37 | Active | YELLOWFEVER | 184 |
| rubella/mumps | 38 | Inactive | MMR | 03 |
| Japanese encephalitis SC | 39 | Inactive | Japanese encephalitis | 129 |
| rabies, intradermal injection | 40 | Inactive | RABIES | 90 |
| typhoid, parenteral | 41 | Inactive | TYPHOID | 91 |
| Hep B, adolescent/high risk infant | 42 | Inactive | HepB | 45 |
| Hep B, adult | 43 | Active | HepB | 45 |
| Hep B, high-dosage, dialysis or IC | 44 | Active | HepB | 45 |
| Hep B, unspecified formulation | 45 | Inactive | HepB | 45 |
| Hib (PRP-D) | 46 | Inactive | HIB | 17 |
| Hib (HbOC) | 47 | Inactive | HIB | 17 |
| Hib (PRP-T) | 48 | Active | HIB | 17 |
| Hib (PRP-OMP) | 49 | Active | HIB | 17 |
| DTaP-Hib | 50 | Inactive | HIB | 17 |
| DTaP-Hib | 50 | Inactive | DTAP | 107 |
| COVID-19 Non-US Vaccine, UNSPECIFIED | 500 | Non-US | COVID-19 | 213 |
| COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | 501 | Non-US | COVID-19 | 213 |
| COVID-19 IV Non-US Vaccine (COVAXIN) | 502 | Non-US | COVID-19 | 213 |
| COVID-19 LAV Non-US Vaccine (COVIVAC) | 503 | Non-US | COVID-19 | 213 |
| COVID-19 VVnr Non-US Vaccine (Sputnik Light) | 504 | Non-US | COVID-19 | 213 |
| COVID-19 VVnr Non-US Vaccine (Sputnik V) | 505 | Non-US | COVID-19 | 213 |
| COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | 506 | Non-US | COVID-19 | 213 |
| COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) | 507 | Non-US | COVID-19 | 213 |
| COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | 508 | Non-US | COVID-19 | 213 |
| COVID-19 PS Non-US Vaccine (EpiVacCorona) | 509 | Non-US | COVID-19 | 213 |
| Hib-Hep B | 51 | Inactive | HIB | 17 |
| Hib-Hep B | 51 | Inactive | HepB | 45 |
| COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 510 | Non-US | COVID-19 | 213 |
| COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 511 | Non-US | COVID-19 | 213 |
| SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 512 | Non-US | COVID-19 | 213 |
| SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | 513 | Non-US | COVID-19 | 213 |
| SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | 514 | Non-US | COVID-19 | 213 |
| SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | 515 | Non-US | COVID-19 | 213 |
| COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | 516 | Non-US | COVID-19 | 213 |
| SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | 517 | Non-US | COVID-19 | 213 |
| COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | 518 | Non-US | COVID-19 | 213 |
| COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | 519 | Non-US | COVID-19 | 213 |
| Hep A, adult | 52 | Active | HepA | 85 |
| COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | 520 | Non-US | COVID-19 | 213 |
| COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | 521 | Non-US | COVID-19 | 213 |
| typhoid, parenteral, AKD (U.S. military) | 53 | Inactive | TYPHOID | 91 |
| adenovirus, type 4 | 54 | Inactive | ADENO | 82 |
| adenovirus, type 7 | 55 | Inactive | ADENO | 82 |
| dengue fever tetravalent | 56 | Active | DENGUE | 330 |
| HPV, quadrivalent | 62 | Active | HPV | 137 |
| Lyme disease | 66 | Inactive | Lyme disease | 66 |
| rotavirus, tetravalent | 74 | Inactive | ROTAVIRUS | 122 |
| Vaccinia (smallpox, monkeypox), live | 75 | Active | Orthopoxvirus | 325 |
| Tick-borne encephalitis vaccine (non-US) | 77 | Non-US | Tick-borne encephalitis | 222 |
| VEE, live | 80 | Inactive | VEE | 92 |
| VEE, inactivated | 81 | Inactive | VEE | 92 |
| adenovirus, unspecified formulation | 82 | Inactive | ADENO | 82 |
| Hep A, ped/adol, 2 dose | 83 | Active | HepA | 85 |
| Hep A, ped/adol, 3 dose | 84 | Inactive | HepA | 85 |
| Hep A, unspecified formulation | 85 | Inactive | HepA | 85 |
| influenza, unspecified formulation | 88 | Inactive | FLU | 88 |
| polio, unspecified formulation | 89 | Inactive | POLIO | 89 |
| rabies, unspecified formulation | 90 | Inactive | RABIES | 90 |
| typhoid, unspecified formulation | 91 | Inactive | TYPHOID | 91 |
| VEE, unspecified formulation | 92 | Inactive | VEE | 92 |
| MMRV | 94 | Active | MMR | 03 |
| MMRV | 94 | Active | VARICELLA | 21 |